| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PSME1 |
| Uniprot No | Q06323 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-249aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMAMLRVQPEAQAKVDVFREDLCTKTENLLG SYFPKKISELDAFLKEPALNEANLSNLKAPLDIPVPDPVKEKEKEERKKQ QEKEDKDEKKKGEDEDKGPPCGPVNCNEKIVVLLQRLKPEIKDVIEQLNL VTTWLQLQIPRIEDGNNFGVAVQEKVFELMTSLHTKLEGFHTQISKYFSE RGDAVTKAAKQPHVGDYRQLVHELDEAEYRDIRLMVMEIRNAYAVLYDII LKNFEKLKKPRGETKGMIY |
| 预测分子量 | 31 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PSME1重组蛋白的3篇代表性文献摘要(文献标题和作者为虚拟示例，供参考)：
---
1. **标题**: *Recombinant PSME1 enhances proteasome activity and promotes antigen presentation in dendritic cells*
**作者**: Zhang Y, et al.
**摘要**: 本研究通过在大肠杆菌系统中表达并纯化重组PSME1蛋白，证实其能够激活20S蛋白酶体的水解活性，并促进树突状细胞对抗原肽的加工和呈递，揭示了PSME1在适应性免疫中的调控机制。
2. **标题**: *Structural insights into PSME1-20S proteasome complex using cryo-EM*
**作者**: Tanaka K, et al.
**摘要**: 利用重组PSME1蛋白与20S蛋白酶体进行体外复合物重构，通过冷冻电镜解析了PSME1结合蛋白酶体的三维结构，阐明了其通过C端螺旋调控蛋白酶体门控开放的分子机制。
3. **标题**: *PSME1 recombinant protein suppresses tumor growth by modulating immune microenvironment*
**作者**: Wang L, et al.
**摘要**: 在哺乳动物细胞中表达人源PSME1重组蛋白，发现其能通过增强肿瘤细胞中抗原肽的产生，促进T细胞介导的抗肿瘤免疫应答，为基于PSME1的癌症免疫治疗提供了实验依据。
---
**注**：以上文献为示例性质，实际研究中请通过PubMed或专业数据库检索真实文献。如需具体文献推荐，可进一步提供研究方向(如结构、疾病、相互作用蛋白等)。
PSME1 (Proteasome Activator Subunit 1), also known as PA28α, is a key component of the 11S regulatory particle of the proteasome, a large protease complex responsible for degrading damaged or misfolded proteins in eukaryotic cells. As part of the PA28 family, PSME1 forms a heterohexameric complex with PA28β (PSME2) or a homoheptameric structure, enhancing the proteasome's ability to cleave peptides in an ATP-independent manner. This activation mechanism is particularly critical for generating antigenic peptides presented by MHC class I molecules, linking PSME1 to adaptive immune responses.
The recombinant PSME1 protein is typically produced using expression systems like *E. coli* or mammalian cell cultures, enabling researchers to study its structure-function relationships without interference from native cellular components. Its recombinant form retains the ability to bind proteasomes and modulate their activity, making it a valuable tool for investigating protein degradation pathways, immune regulation, and stress responses. Studies using PSME1 recombinant proteins have revealed its role in various diseases, including cancer (where its overexpression correlates with tumor progression), neurodegenerative disorders (through protein clearance mechanisms), and autoimmune conditions.
Recent structural studies using recombinant PSME1 have mapped critical interaction domains with the 20S proteasome core, while biochemical assays demonstrate its capacity to enhance hydrolysis of small fluorogenic substrates. However, unresolved questions remain regarding its substrate specificity and tissue-specific regulatory mechanisms. The development of PSME1 recombinant proteins continues to support drug discovery efforts targeting proteasome dysregulation, particularly in immunotherapy and proteostasis-related therapies.
×
